Alice B Gottlieb Selected Research

Psoriasis (Pustulosis Palmaris et Plantaris)

5/2022	Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis.
5/2022	Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials.
4/2022	Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
4/2022	Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
2/2022	Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12.
2/2022	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
1/2022	Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
1/2022	Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis.
1/2022	Clinical Disease Measures in Generalized Pustular Psoriasis.
12/2021	Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alice B Gottlieb Research Topics

Disease

165	Psoriasis (Pustulosis Palmaris et Plantaris) 05/2022 - 05/2002
57	Psoriatic Arthritis 07/2022 - 09/2003
25	Infections 01/2022 - 11/2003
15	Neoplasms (Cancer) 12/2021 - 12/2005
8	Inflammation (Inflammations) 08/2018 - 12/2002
6	Metabolic Syndrome (Dysmetabolic Syndrome X) 02/2021 - 01/2008
6	Pain (Aches) 01/2018 - 10/2010
5	Arthritis (Polyarthritis) 01/2022 - 01/2006
5	Necrosis 01/2018 - 02/2009
5	Skin Diseases (Skin Disease) 10/2016 - 05/2003
5	Atopic Dermatitis (Atopic Eczema) 10/2016 - 08/2005
5	Rheumatoid Arthritis 01/2016 - 01/2004
5	Skin Neoplasms (Skin Cancer) 07/2015 - 12/2008
4	Ankylosing Spondylitis 04/2022 - 01/2012
3	Body Weight (Weight, Body) 05/2022 - 01/2008
3	Vitiligo 01/2022 - 06/2017
3	Tuberculosis (Tuberculoses) 12/2021 - 05/2007
3	Pruritus (Itching) 11/2020 - 04/2016
3	Cardiovascular Diseases (Cardiovascular Disease) 12/2014 - 01/2008
3	Autoimmune Diseases (Autoimmune Disease) 04/2013 - 05/2007
2	Injection Site Reaction 12/2021 - 01/2012
2	Hyperlipidemias (Hyperlipidemia) 02/2021 - 08/2011
2	Hypertension (High Blood Pressure) 02/2021 - 08/2011
2	Obesity 02/2021 - 08/2011
2	Acne Vulgaris 11/2020 - 03/2004
2	Hidradenitis Suppurativa 06/2020 - 08/2016
2	Pyoderma Gangrenosum 11/2016 - 11/2012
2	Dermatomyositis (Dermatopolymyositis) 11/2016 - 11/2008
2	Nasopharyngitis 10/2016 - 09/2015
2	Nail Diseases (Nail Disease) 12/2012 - 05/2007
2	Allergic Contact Dermatitis 03/2012 - 11/2006
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2012 - 11/2010
2	Tetanus 06/2010 - 11/2003

Drug/Important Bio-Agent (IBA)

35	Biological ProductsIBA 02/2022 - 11/2002
29	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2019 - 12/2002
27	Etanercept (Enbrel)FDA Link 05/2022 - 11/2003
24	Monoclonal AntibodiesIBA 01/2022 - 11/2002
24	Ustekinumab (CNTO 1275)FDA Link 01/2021 - 06/2010
19	Infliximab (Remicade)FDA Link 01/2021 - 01/2003
17	Tumor Necrosis Factor InhibitorsIBA 01/2019 - 11/2003
16	secukinumabIBA 05/2022 - 09/2013
14	CytokinesIBA 01/2020 - 11/2002
10	apremilastIBA 02/2021 - 03/2012
10	Adalimumab (Humira)FDA Link 01/2020 - 07/2006
10	efalizumab (Raptiva)FDA Link 07/2006 - 05/2002
9	InterleukinsIBA 04/2022 - 06/2010
9	Pharmaceutical PreparationsIBA 02/2021 - 06/2003
9	Methotrexate (Mexate)FDA LinkGeneric 06/2020 - 01/2008
9	Prostaglandins AIBA 01/2019 - 05/2003
9	Alefacept (Amevive)FDA Link 09/2011 - 11/2003
8	Cyclosporine (Ciclosporin)FDA LinkGeneric 02/2020 - 08/2003
8	Interleukin-12 (IL 12)IBA 06/2014 - 12/2004
7	Immunoglobulin A (IgA)IBA 05/2022 - 03/2016
7	guselkumabIBA 02/2022 - 01/2018
7	Interleukin-17 (Interleukin 17)IBA 11/2020 - 11/2014
7	C-Reactive ProteinIBA 11/2020 - 08/2013
7	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2020 - 05/2003
6	Interleukin-23 (Interleukin 23)IBA 02/2022 - 01/2012
5	bimekizumabIBA 07/2022 - 08/2018
5	tildrakizumabIBA 05/2022 - 01/2020
5	Biomarkers (Surrogate Marker)IBA 01/2014 - 07/2008
4	ixekizumabIBA 04/2022 - 09/2018
4	Proteins (Proteins, Gene)FDA Link 10/2006 - 11/2002
3	ruxolitinibIBA 01/2022 - 06/2017
3	Antirheumatic Agents (DMARD)IBA 01/2021 - 05/2014
3	Mycophenolic Acid (Cellcept)FDA LinkGeneric 06/2020 - 09/2009
3	Hydroxyurea (Hydrea)FDA LinkGeneric 06/2020 - 11/2008
3	Tacrolimus (Prograf)FDA LinkGeneric 06/2020 - 08/2005
3	Leflunomide (Arava)FDA LinkGeneric 06/2020 - 09/2009
3	Acitretin FDA Link 02/2020 - 07/2007
3	omega-Chloroacetophenone (Mace)IBA 10/2017 - 12/2014
3	Immunoglobulins (Immunoglobulin)IBA 10/2010 - 04/2006
3	RetinoidsIBA 01/2008 - 07/2005
3	Immunoglobulin G (IgG)IBA 01/2006 - 11/2002
2	Interleukin-23 Subunit p19IBA 02/2022 - 01/2020
2	FumaratesIBA 06/2020 - 09/2009
2	Thioguanine (Tioguanine)FDA Link 06/2020 - 09/2009
2	Certolizumab Pegol FDA Link 08/2018 - 01/2018
2	Abatacept (Orencia)FDA Link 09/2017 - 02/2015
2	ametantrone (HAQ)IBA 12/2016 - 06/2014
2	InterferonsIBA 11/2016 - 12/2009
2	Messenger RNA (mRNA)IBA 08/2015 - 05/2007
2	golimumab FDA Link 07/2014 - 05/2010
2	Phosphodiesterase 4 InhibitorsIBA 04/2013 - 03/2012
2	tazarotene (Tazorac)FDA Link 09/2011 - 11/2002
2	Immunomodulating AgentsIBA 11/2010 - 08/2003
2	AntigensIBA 06/2010 - 09/2003
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2008 - 06/2005
2	ChemokinesIBA 05/2007 - 10/2006
2	Interleukin-8 (Interleukin 8)IBA 05/2007 - 08/2005
2	pimecrolimus (Elidel)FDA Link 09/2005 - 11/2004

Therapy/Procedure

61	Therapeutics 01/2022 - 05/2003
12	Biological Therapy 05/2022 - 11/2002
10	Phototherapy (Light Therapy) 02/2020 - 12/2009
3	Immunomodulation 11/2010 - 04/2003
3	Immunotherapy 01/2004 - 01/2003
2	Subcutaneous Injections 01/2020 - 01/2008
2	Excimer Lasers 09/2019 - 01/2012
2	Aftercare (After-Treatment) 10/2016 - 06/2008
2	Oral Administration 01/2012 - 10/2008